These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 28183282)

  • 1. Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide.
    Tobias J; Jasinska J; Baier K; Kundi M; Ede N; Zielinski C; Wiedermann U
    BMC Cancer; 2017 Feb; 17(1):118. PubMed ID: 28183282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
    Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
    Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study.
    Wiedermann U; Wiltschke C; Jasinska J; Kundi M; Zurbriggen R; Garner-Spitzer E; Bartsch R; Steger G; Pehamberger H; Scheiner O; Zielinski CC
    Breast Cancer Res Treat; 2010 Feb; 119(3):673-83. PubMed ID: 20092022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu.
    Jasinska J; Wagner S; Radauer C; Sedivy R; Brodowicz T; Wiltschke C; Breiteneder H; Pehamberger H; Scheiner O; Wiedermann U; Zielinski CC
    Int J Cancer; 2003 Dec; 107(6):976-83. PubMed ID: 14601058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effect of new HER2 peptide vaccination based on B cell epitope.
    Miyako H; Kametani Y; Katano I; Ito R; Tsuda B; Furukawa A; Saito Y; Ishikawa D; Ogino K; Sasaki S; Imai K; Habu S; Makuuchi H; Tokuda Y
    Anticancer Res; 2011 Oct; 31(10):3361-8. PubMed ID: 21965747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer.
    Gillogly ME; Kallinteris NL; Xu M; Gulfo JV; Humphreys RE; Murray JL
    Cancer Immunol Immunother; 2004 Jun; 53(6):490-6. PubMed ID: 14740174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of Her-2/neu vaccine utilizing idiotypic network cascade.
    Pal S; Saha A; Mohanty K; Mallick P; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
    Cancer Biol Ther; 2007 Dec; 6(12):1916-25. PubMed ID: 18059165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer-Results from Phase Ib Trial IMU.ACS.001.
    Wiedermann U; Garner-Spitzer E; Chao Y; Maglakelidze M; Bulat I; Dechaphunkul A; Arpornwirat W; Charoentum C; Yen CJ; Yau TC; Tanasanvimon S; Maneechavakajorn J; Sookprasert A; Bai LY; Chou WC; Ungtrakul T; Drinic M; Tobias J; Zielinski CC; Chong L; Ede NJ; Marino MT; Good AJ
    Clin Cancer Res; 2021 Jul; 27(13):3649-3660. PubMed ID: 33879458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors.
    Sotiriadou NN; Kallinteris NL; Gritzapis AD; Voutsas IF; Papamichail M; von Hofe E; Humphreys RE; Pavlis T; Perez SA; Baxevanis CN
    Cancer Immunol Immunother; 2007 May; 56(5):601-13. PubMed ID: 16960693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
    Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
    Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine.
    Maruyama H; Zaloudik J; Li W; Sperlagh M; Koido T; Somasundaram R; Scheck S; Prewett M; Herlyn D
    Cancer Immunol Immunother; 2000 Jun; 49(3):123-32. PubMed ID: 10881691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu.
    Riemer AB; Klinger M; Wagner S; Bernhaus A; Mazzucchelli L; Pehamberger H; Scheiner O; Zielinski CC; Jensen-Jarolim E
    J Immunol; 2004 Jul; 173(1):394-401. PubMed ID: 15210798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse.
    Singh R; Dominiecki ME; Jaffee EM; Paterson Y
    J Immunol; 2005 Sep; 175(6):3663-73. PubMed ID: 16148111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
    Disis ML; Grabstein KH; Sleath PR; Cheever MA
    Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.
    Zamani P; Teymouri M; Nikpoor AR; Navashenaq JG; Gholizadeh Z; Darban SA; Jaafari MR
    Eur J Cancer; 2020 Apr; 129():80-96. PubMed ID: 32145473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
    Dakappagari NK; Pyles J; Parihar R; Carson WE; Young DC; Kaumaya PT
    J Immunol; 2003 Apr; 170(8):4242-53. PubMed ID: 12682258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation of HBsAg in Montanide ISA 51VG adjuvant: Immunogenicity study and monitoring long-lived humoral immune responses.
    Savoji MA; Sereshgi MMA; Ghahari SMM; Asgarhalvaei F; Mahdavi M
    Int Immunopharmacol; 2021 Jul; 96():107599. PubMed ID: 33848910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
    Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design.
    Yip YL; Smith G; Koch J; Dübel S; Ward RL
    J Immunol; 2001 Apr; 166(8):5271-8. PubMed ID: 11290813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo.
    Allen SD; Garrett JT; Rawale SV; Jones AL; Phillips G; Forni G; Morris JC; Oshima RG; Kaumaya PT
    J Immunol; 2007 Jul; 179(1):472-82. PubMed ID: 17579068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.